Quick Facts

Paradigm shifting immunotherapy For complex, unmet clinical need indications

Paradigm shifting immunotherapy
For complex, life-threatening indications without therapies

Advanced clinical-stage pipeline with promising phase 2a results

Advanced clinical-stage pipeline
Promising results of PhIb (sepsis) and PhIIa (GvHD) studies, initiating Sepsis Phase IIb study

Advanced clinical-stage pipeline with promising phase 2a results

Multi-billion dollar
underserved markets

Sepsis | Solid Tumors, Covid-19,
Bone-Marrow Transplantations

Short regulatory approval pathway FDA & EU orphan designations; Specialized life-threatening regulation in Europe potentially enabling post-Phase II marketing approval

Short regulatory approval pathway
Specialized regulation in Europe potentially enabling post-Phase II marketing approval

Strong leadership Previously founded and managed PROLOR Biotech, sold For $560M; Signed partnership with Pfizer, $295 Million down payment

Strong leadership
Previously founded and managed PROLOR Biotech, a $560M exit event; Signed partnership with Pfizer, $295 Million down payment

Cash balance $30 Million invested; Expected cash balance of 2.5 Years at closing, Next clinical milestone within 12 months

Cash balance
~$60 Million invested; Cash balance supporting multiple clinical milestone within 18-24 months

Latest news & events

SEC Filings

Date Form Description Download

Corporate Governance

Charter of the Audit Committee of the Board of Directors download
Charter of the Compensation Committee of the Board of Directors download
Code of Business Conduct and Ethics download
Disclosure Policy download
Employee Complaint Procedures for Accounting and Auditing Matters download
Insider Trading Policy download
Download our company overview

Find out more

14 Einstein St. Nes-Ziona, Israel, 7403618
T +972.2.6708072  |  F +972.2.6708070
info@enlivex.com